U.S. Markets open in 2 hrs 52 mins

Nevro Announces Completion of Patient Enrollment in Largest Multicenter Randomized Controlled Trial of High Frequency Spinal Cord Stimulation for Painful Diabetic Neuropathy

REDWOOD CITY, Calif., Aug. 28, 2019 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain conditions, today announced that it has completed patient enrollment in its prospective, multicenter Randomized Controlled Trial (RCT) for the treatment of chronic pain for patients who suffer from Painful Diabetic Neuropathy (PDN).

"This is an important step in the evaluation of Nevro's Senza HF10 therapy for this very large and often undertreated patient population," said D. Keith Grossman, Nevro's Chairman, CEO and President.  "Diabetes affects nearly one in ten adults in the United States and can damage peripheral nerves, resulting in severe pain and numbness in the hands and feet.  According to published literature, there are approximately 4 million diabetic patients suffering from painful diabetic neuropathy in the U.S. alone.  The SENZA-PDN study compares HF10 therapy plus Conventional Medical Management (CMM) to CMM alone in 216 patients at 18 centers in the United States. The primary endpoint of the study is the difference in proportion of treatment responders at 3-month follow-up and the study will collect outcomes out to 24 months. This RCT is designed to provide safety and efficacy data, which will be used to support customer adoption and efforts to ensure adequate payor coverage of this procedure.  We thank Dr. Erika Petersen, Director of Functional and Restorative Neurosurgery at UAMS, for serving as the lead Principal Investigator for this study."

About Nevro Corp. 
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
650-433-3247
ir@nevro.com

 

.

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-announces-completion-of-patient-enrollment-in-largest-multicenter-randomized-controlled-trial-of-high-frequency-spinal-cord-stimulation-for-painful-diabetic-neuropathy-300908153.html